It has also been reported that anti-PrPC mAb 6D11 blocks the Aβo binding site on PrPC preventing the impairment in long-term potentiation (LTP) caused by Aβo derived from AD brain extracts (Barry et al., 2011; Freir et al., 2011), suggesting that 6D11 and possibly antibodies with a similar epitope have therapeutic potential in multiple neurodegenerative diseases. Here, ABO is linked to Alzheimer disease.